TONIX PHARMACEUTICALS HOLDING CORP. Cash and Cash Equivalents, Period Increase (Decrease)
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$10.81 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-11-09
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$2.00M.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$2.57M, a 117.86% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$6.24M, a 723.05% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$3.81M, a 217.21% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $6.55M.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$277.00K.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$19.01M, a 163.40% decline from fiscal 2014.
- TONIX PHARMACEUTICALS HOLDING CORP. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $29.98M, a 367.23% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|
| 2018-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$4.57M derived: sum of 2 quarters · filed 2018-11-09 | -$10.81M 10-Q · filed 2018-11-09 | -$14.63M derived: sum of 4 quarters · filed 2018-11-09 | |
| 2018-06-30 | -$2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | -$8.82M 10-Q · filed 2018-08-13 | -$12.63M derived: sum of 3 quarters · filed 2018-08-13 | -$17.68M derived: sum of 4 quarters · filed 2018-11-09 | |
| 2018-03-31 | -$6.24M 10-Q · filed 2018-05-11 | -$10.06M derived: sum of 2 quarters · filed 2018-05-11 | -$15.10M derived: sum of 3 quarters · filed 2018-11-09 | -$690.00K derived: sum of 4 quarters · filed 2018-11-09 | |
| 2017-12-31 | -$3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$8.86M derived: sum of 2 quarters · filed 2018-11-09 | $5.55M derived: sum of 3 quarters · filed 2018-11-09 | $6.55M 10-K · filed 2018-03-09 | |
| 2017-09-30 | -$5.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $9.37M derived: sum of 2 quarters · filed 2018-11-09 | $10.37M 10-Q · filed 2018-11-09 | $13.62M derived: sum of 4 quarters · filed 2018-11-09 | |
| 2017-06-30 | $14.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $15.41M 10-Q · filed 2018-08-13 | $18.67M derived: sum of 3 quarters · filed 2018-08-13 | $19.37M derived: sum of 4 quarters · filed 2018-08-13 | |
| 2017-03-31 | $1.00M 10-Q · filed 2018-05-11 | $4.26M derived: sum of 2 quarters · filed 2018-05-11 | $4.96M derived: sum of 3 quarters · filed 2018-05-11 | $11.47M derived: sum of 4 quarters · filed 2018-05-11 | |
| 2016-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $3.96M derived: sum of 2 quarters · filed 2018-03-09 | $10.47M derived: sum of 3 quarters · filed 2018-03-09 | -$277.00K 10-K · filed 2018-03-09 | -$234.00K 10-K · filed 2017-04-13 |
| 2016-09-30 | $706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $7.22M derived: sum of 2 quarters · filed 2017-11-06 | -$3.53M 10-Q · filed 2017-11-06 | -$17.36M derived: sum of 4 quarters · filed 2017-11-06 | |
| 2016-06-30 | $6.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | -$4.24M 10-Q · filed 2017-08-11 | -$18.07M derived: sum of 3 quarters · filed 2017-08-11 | -$33.80M derived: sum of 4 quarters · filed 2017-08-11 | |
| 2016-03-31 | -$10.75M 10-Q · filed 2017-05-12 | -$24.58M derived: sum of 2 quarters · filed 2017-05-12 | -$40.31M derived: sum of 3 quarters · filed 2017-05-12 | -$49.75M derived: sum of 4 quarters · filed 2017-05-12 | |
| 2015-12-31 | -$13.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-13 | -$29.56M derived: sum of 2 quarters · filed 2017-04-13 | -$39.01M derived: sum of 3 quarters · filed 2017-04-13 | -$19.01M 10-K · filed 2017-04-13 | |
| 2015-09-30 | -$15.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$25.17M derived: sum of 2 quarters · filed 2016-11-10 | -$5.17M 10-Q · filed 2016-11-10 | -$13.22M derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | -$9.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $10.55M 10-Q · filed 2016-08-05 | $2.51M derived: sum of 3 quarters · filed 2016-08-05 | $4.87M derived: sum of 4 quarters · filed 2016-08-05 | |
| 2015-03-31 | $20.00M 10-Q · filed 2016-05-06 | $11.95M derived: sum of 2 quarters · filed 2016-05-06 | $14.31M derived: sum of 3 quarters · filed 2016-05-06 | ||
| 2014-12-31 | -$8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | -$5.69M derived: sum of 2 quarters · filed 2016-03-03 | $29.98M 10-K · filed 2016-03-03 | ||
| 2014-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $38.02M 10-Q · filed 2015-11-06 | |||
| 2014-06-30 | $35.67M 10-Q · filed 2015-08-07 | ||||
| 2013-12-31 | $6.42M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |